A single-arm phase II-study to confirm efficacy and feasibility of tarlatamab treatment in patients with extensive stage small-cell lung cancer with poor performance status (SPACE-T) [without IMPD-Q]

2025-522437-65-00 · tracked via the Priya Life Science EU tracker

Sponsor

AIO-Studien gGmbH

Sponsor type

Laboratory/Research/Testing facility

Therapeutic area

Neoplasms

Decision date

31/10/2025

Enrollment target

Sites

Germany

Condition studied

small-cell lung cancer

Investigational medicinal product(s)

Tarlatamab

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Primary endpoint

Overall survival (OS) rate at 12 months

Endpoint detail

Overall survival (OS), Progression-free survival (PFS), Objective response rate (ORR) (RECIST v1.1), intracranial ORR (RECIST v1.1), Rate of patients tolerating tarlatamab until first disease assessment, Time to next-line systemic therapy, Safety and tolerability, Quality of life: o EORTC-QLQ-C30 o PRO CTCAE

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522437-65-00 on CTIS ↗ ← All trials in the EU